950220.KQ
Price:
$1939
Market Cap:
$13.00B
As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in clinical development for its potential to treat a range of oncologic and infectious conditions. Founded in 2014, NeoImmuneTech is based in Rockville, Maryland.
Industry
Biotechnology
IPO Date
2021-03-16
Stock Exchange
KOE
Ticker
950220.KQ
According to NeoImmuneTech, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.40. This represents a change of -30.69% compared to the average of -7.79 of the last 4 quarters.
The mean historical PE Ratio of NeoImmuneTech, Inc. over the last ten years is -1143.99. The current -5.40 PE Ratio has changed -52.80% with respect to the historical average. Over the past ten years (40 quarters), 950220.KQ's PE Ratio was at its highest in in the March 2019 quarter at 0. The PE Ratio was at its lowest in in the September 2019 quarter at -1932.92.
Average
-1143.99
Median
-244.12
Minimum
-5013.98
Maximum
-0.54
Discovering the peaks and valleys of NeoImmuneTech, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 462.32%
Maximum Annual PE Ratio = -0.54
Minimum Annual Increase = -99.73%
Minimum Annual PE Ratio = -5013.98
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -3.05 | 462.32% |
| 2024 | -0.54 | -30.50% |
| 2023 | -0.78 | -41.11% |
| 2022 | -1.33 | -99.73% |
| 2021 | -485.19 | -58.18% |
| 2020 | -1160.06 | -53.35% |
| 2019 | -2487.00 | -50.40% |
The current PE Ratio of NeoImmuneTech, Inc. (950220.KQ) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.46
5-year avg
-98.18
10-year avg
-1143.99
NeoImmuneTech, Inc.’s PE Ratio is
| Company | PE Ratio | Market cap |
|---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeoImmuneTech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeoImmuneTech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NeoImmuneTech, Inc.'s PE Ratio?
How is the PE Ratio calculated for NeoImmuneTech, Inc. (950220.KQ)?
What is the highest PE Ratio for NeoImmuneTech, Inc. (950220.KQ)?
What is the 3-year average PE Ratio for NeoImmuneTech, Inc. (950220.KQ)?
What is the 5-year average PE Ratio for NeoImmuneTech, Inc. (950220.KQ)?
How does the current PE Ratio for NeoImmuneTech, Inc. (950220.KQ) compare to its historical average?